$VIRI: Virios Therapeutics, Inc. - Common Stock

Virios Therapeutics, Inc. (NASDAQ: VIRI) is a clinical-stage biotechnology company developing targeted antiviral therapeutics with the potential to provide single-dose, orally delivered treatment for a range of serious viral infections. The company's lead product candidate, VIR-001, is a first-in-class, orally delivered, small molecule antiviral that is in Phase 2 clinical development for the treatment of human cytomegalovirus (HCMV) infection. HCMV is a common and potentially life-threatening virus that can cause serious complications in immunocompromised patients, such as those with HIV/AIDS, cancer, or organ transplants. VIR-001 has the potential to be a best-in-class antiviral for HCMV, with the ability to provide a single-dose, oral treatment that is well-tolerated and has a favorable safety profile.

In addition to VIR-001, Virios is also developing a pipeline of other antiviral product candidates, including VIR-002, a small molecule antiviral that is in preclinical development for the treatment of influenza A and B viruses. VIR-002 has the potential to be a fast-acting, single-dose antiviral that could be used to treat influenza during the early stages of infection, before the virus has a chance to spread.

Virios is a well-funded company with a strong management team. The company has raised over $100 million in funding to date, and it has a board of directors that includes experienced pharmaceutical executives. Virios is well-positioned to develop and commercialize its pipeline of antiviral products, and it has the potential to make a significant impact on the treatment of serious viral infections.

Here is a more detailed overview of Virios's product pipeline:

• VIR-001: VIR-001 is a first-in-class, orally delivered, small molecule antiviral that is in Phase 2 clinical development for the treatment of HCMV infection. HCMV is a common and potentially life-threatening virus that can cause serious complications in immunocompromised patients, such as those with HIV/AIDS, cancer, or organ transplants. VIR-001 has the potential to be a best-in-class antiviral for HCMV, with the ability to provide a single-dose, oral treatment that is well-tolerated and has a favorable safety profile.
• VIR-002: VIR-002 is a small molecule antiviral that is in preclinical development for the treatment of influenza A and B viruses. VIR-002 has the potential to be a fast-acting, single-dose antiviral that could be used to treat influenza during the early stages of infection, before the virus has a chance to spread.
• VIR-003: VIR-003 is a small molecule antiviral that is in preclinical development for the treatment of respiratory syncytial virus (RSV) infection. RSV is a common respiratory virus that can cause serious complications in infants, young children, and the elderly. VIR-003 has the potential to be a safe and effective treatment for RSV infection, with the potential to reduce the risk of hospitalization and death.

Virios is a promising biotechnology company with a strong pipeline of antiviral product candidates. The company is well-funded and has a experienced management team. Virios is well-positioned to develop and commercialize its products, and it has the potential to make a significant impact on the treatment of serious viral infections.